Diffuse Large B-cell Lymphoma Cell-of-origin Classification Using the Lymph2Cx Assay in the Context of BCL2 and MYC Expression Status

Overview

Journal Leuk Lymphoma

Specialties Hematology
Oncology

Date 2015 Oct 6

PMID 26437080

Citations 6

Authors

Samantha Kendrick

Katalin Tus

George Wright

Elaine S Jaffe

Andreas Rosenwald

Elias Campo

Wing Chung Chan

Joseph M Connors

Rita M Braziel

German Ott

Jan Delabie

James R Cook

Dennis D Weisenburger

Timothy C Greiner

Kai Fu

Louis M Staudt

Randy D Gascoyne

David W Scott

Lisa M Rimsza

Affiliations

Soon will be listed here.

Citing Articles

A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.

Zhang W, Ao Q, Guan Y, Zhu Z, Kuang D, Li M Mod Pathol. 2021; 35(5):632-639.

PMID: 34802044 PMC: 9042706. DOI: 10.1038/s41379-021-00954-z.

A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.

Xu-Monette Z, Zhang H, Zhu F, Tzankov A, Bhagat G, Visco C Blood Adv. 2020; 4(14):3391-3404.

PMID: 32722783 PMC: 7391158. DOI: 10.1182/bloodadvances.2020001949.

Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.

Abdulla M, Hollander P, Pandzic T, Mansouri L, Ednersson S, Andersson P Am J Hematol. 2019; 95(1):57-67.

PMID: 31659781 PMC: 6916573. DOI: 10.1002/ajh.25666.

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.

Nowakowski G, Feldman T, Rimsza L, Westin J, Witzig T, Zinzani P Blood Cancer J. 2019; 9(6):48.

PMID: 31097684 PMC: 6522601. DOI: 10.1038/s41408-019-0208-6.

Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities.

Morgan E, Sweeney M, Tomoka T, Kopp N, Gusenleitner D, Redd R Blood Adv. 2018; 1(1):84-92.

PMID: 29296697 PMC: 5744047. DOI: 10.1182/bloodadvances.2016000026.

References

Johnson N, Slack G, Savage K, Connors J, Ben-Neriah S, Rogic S . Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30(28):3452-9. PMC: 3454768. DOI: 10.1200/JCO.2011.41.0985. View

Scott D, Wright G, Williams P, Lih C, Walsh W, Jaffe E . Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014; 123(8):1214-7. PMC: 3931191. DOI: 10.1182/blood-2013-11-536433. View

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

Kendrick S, Redd L, Muranyi A, Henricksen L, Stanislaw S, Smith L . BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Hum Pathol. 2014; 45(10):2144-53. PMC: 4197184. DOI: 10.1016/j.humpath.2014.06.005. View

Horn H, Ziepert M, Becher C, Barth T, Bernd H, Feller A . MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013; 121(12):2253-63. DOI: 10.1182/blood-2012-06-435842. View

Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H . Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-23. PMC: 9103713. DOI: 10.1056/NEJMoa0802885. View

Perry A, Alvarado-Bernal Y, Laurini J, Smith L, Slack G, Tan K . MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol. 2014; 165(3):382-91. DOI: 10.1111/bjh.12763. View

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

Green T, Young K, Visco C, Xu-Monette Z, Orazi A, Go R . Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30(28):3460-7. DOI: 10.1200/JCO.2011.41.4342. View

10.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

11.

Brown R, Danford F, Gokhale V, Hurley L, Brooks T . Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J Biol Chem. 2011; 286(47):41018-27. PMC: 3220475. DOI: 10.1074/jbc.M111.274720. View

12.

Hu S, Xu-Monette Z, Tzankov A, Green T, Wu L, Balasubramanyam A . MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium.... Blood. 2013; 121(20):4021-31. PMC: 3709650. DOI: 10.1182/blood-2012-10-460063. View

13.

Zaman S, Wang R, Gandhi V . Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma. 2013; 55(9):1980-92. PMC: 4152229. DOI: 10.3109/10428194.2013.855307. View